Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EVOQ Therapeutics

- PMLiVE

AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

Moves a step closer to the rheumatoid arthritis market

- PMLiVE

NICE backs Pfizer’s Xeljanz for RA

But UK’s cost-effectiveness watchdog removes two drugs from CDF

- PMLiVE

NICE backs Sanofi’s Kevzara for routine NHS use

Recommends the RA treatment in combination with methotrexate

- PMLiVE

FDA wants more data on J&J’s arthritis drug Plivensia

Requests further evidence on the drug’s safety profile after patient deaths link

- PMLiVE

Gilead makes $11.9bn play for CAR-T specialist Kite

The agreement is due to close in this year’s fourth quarter

Gilead Sciences

People at-risk of HIV in England could get PrEP from September

10,000 people will use Gilead’s Truvada in the upcoming trial

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Research Partnership

- PMLiVE

Gilead gets OK for three-in-one hep C therapy in US

FDA clears the new product for the most common HCV genotypes

Sanofi reception

Sanofi and Regeneron bag EU approval for arthritis drug Kevzara

The IL-6 inhibitor will be used in combination with methotrexate for adults with RA

- PMLiVE

Samsung Bioepis wins CHMP nod for second Humira biosimilar

In addition to Imraldi the regulatory advisors also backed new medicines from AbbVie and Gilead

- PMLiVE

Lilly and NRAS launch arthritis awareness film campaign

Pharma firm's ‘Behind The Smile’ initiative coincides with RA awareness week

- PMLiVE

Gilead plans fightback against HIV arch-rival ViiV

Descovy sees phase III success after the TAF-based drug proves non-inferior to Triumeq

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links